Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Brunner, Andrew M., Esteve, Jordi, Porkka, Kimmo, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Traer, Elie, Scholl, Sebastian, Garcia-Manero, Guillermo, Vey, Norbert, Wermke, Martin, Janssen, Jeroen J. W. M., Narayan, Rupa, Fleming, Shaun, Loo, Sun, Tovar, Natalia, Kontro, Mika, Ottmann, Oliver G., Naidu, Purushotham, Sun, Haiying, Han, May, White, Roisin, Zhang, Na, Mohammed, Anisa, Sabatos?Peyton, Catherine A., Steensma, David P., Rinne, Mikael L., Borate, Uma M. and Wei, Andrew H. 2024. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American Journal of Hematology 99 (2) , E32-E36. 10.1002/ajh.27161

PDF - Accepted Post-Print Version Download (320kB)

Abstract

The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	0361-8609
Date of First Compliant Deposit:	6 February 2024
Date of Acceptance:	2 November 2023
Last Modified:	22 Nov 2024 02:45
URI:	https://orca.cardiff.ac.uk/id/eprint/166141

Actions (repository staff only)

Edit Item